Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers

Pharmacological Research

Volumn 60, Issue 6, 2009, Pages 508-514

  Kurz, K ^a,b   Teerlink, T ^c   Sarcletti, M ^a   Weiss, G ^b   Zangerle, R ^a   Fuchs, D ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADMA; HIV 1 infection; Immune activation; Neopterin

Indexed keywords

ARGININE; C REACTIVE PROTEIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NEOPTERIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; AGED; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TH1 CELLS; YOUNG ADULT;

EID: 70350044725     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.009     Document Type: Review

References (45)

1. Mildvan D., Spritzler J., Grossberg S.E., Fahey J.L., Johnston D.M., Schock B.R., et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 40 (2005) 853-858
2. Fuchs D., Spira T.J., Hausen A., Reibnegger G., Werner E.R., Werner-Felmayer G., et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 35 (1989) 1746-1749
3. Fahey J.L., Taylor J.M., Detels R., Hofmann B., Melmed R., Nishanian P., et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322 (1990) 166-172
4. Krämer A., Biggar R.J., Hampl H., Friedman R.M., Fuchs D., Wachter H., et al. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am J Epidemiol 136 (1992) 71-80
5. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 160 (1984) 310-316
6. Wirleitner B., Reider D., Ebner S., Böck G., Widner B., Jaeger M., et al. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 72 (2002) 1148-1153
7. Fuchs D., Shearer G.M., Boswell R.N., Clerici M., Reibnegger G., Werner E.R., et al. Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol 80 (1990) 44-48
8. Wirleitner B., Schroecksnadel K., Winkler C., and Fuchs D. Neopterin in HIV-1 infection. Mol Immunol 42 (2005) 183-194
9. Murr C., Widner B., Wirleitner B., and Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metabol 3 (2002) 175-187
10. van Haelst P.L., Liem A., van Boven A.J., Veeger N.J., van Veldhuisen D.J., Tervaert J.W., et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 92 (2003) 1201-1203
11. Ray K.K., Morrow D.A., Sabatine M.S., Shui A., Rifai N., Cannon C.P., et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115 (2007) 3071-3078
12. Avanzas P., Arroyo-Espliguero R., Cosín-Sales J., Aldama G., Pizzi C., Quiles J., et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 90 (2004) 847-852
13. Grammer T.B., Fuchs D., Böhm B.O., Winkelmann B.R., and Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 55 (2009) 115-146
14. Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
15. Lohse N., Hansen A.B., Pedersen G., Kronborg G., Gerstoft J., Sørensen H.T., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146 (2007) 87-95
16. Henry K., Melroe H., Huebsch J., Hermundson J., Levine C., Swensen L., et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351 (1998) 1328
17. Vittecoq D., Escaut L., and Monsuez J.J. Vascular complications associated with use of HIV protease inhibitors. Lancet 351 (1998) 1959
18. Dube M.P., Lipshultz S.E., Fichtenbaum C.J., Greenberg R., Schecter A.D., and Fisher S.D. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 118 (2008) e36-e40
19. Grinspoon S.K., Grunfeld C., Kotler D.P., Currier J.S., Lundgren J.D., Dubé M.P., et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 118 (2008) 198-210
20. Zangerle R., and Fuchs D. Increased cardiovascular risk in patients with human immunodeficiency virus infection under highly active antiretroviral therapy. Am J Cardiol 102 (2008) 373-374
21. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
22. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
23. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 53 (2002) 31-47
24. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
25. Shah S.H., and Newby L.K. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 11 (2003) 169-179
26. Böger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119 (2009) 1592-1600
27. Valkonen V.P., Päivä H., Salonen J.T., Lakka T.A., Lehtimäki T., Laakso J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
28. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
29. Siroen M.P., Teerlink T., Nijveldt R.J., Prins H.A., Richir M.C., and van Leeuwen P.A. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 26 (2006) 203-228
30. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
31. Schroecksnadel K., Weiss G., Stanger O., Teerlink T., and Fuchs D. Increased asymmetric dimethylarginine concentrations in stimulated peripheral blood mononuclear cells. Scand J Immunol 65 (2007) 525-529
32. Murr C., Meinitzer A., Grammer T., Schroecksnadel K., Böhm B.O., März W., et al. Association between asymmetric dimethylarginine and neopterin in patients with and without angiographic coronary artery disease. Scand J Immunol 70 (2009) 63-67
33. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
34. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
35. de Jong S., and Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 353 (2006) 287-289
36. Teerlink J. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. Chromatogr B 851 (2007) 21-29
37. Willemsen N.M., Hitchen E.M., Bodetti T.J., Apolloni A., Warrilow D., Piller S.C., et al. Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology 3 (2006) 92
38. Boulanger M.C., Liang C., Russell R.S., Lin R., Bedford M.T., Wainberg M.A., et al. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol 79 (2005) 124-131
39. Invernizzi C.F., Xie B., Frankel F.A., Feldhammer M., Roy B.B., Richard S., et al. Arginine methylation of the HIV-1 nucleocapsid protein results in its diminished function. AIDS 21 (2007) 795-805
40. Ollenschläger G., Jansen S., Schindler J., Rasokat H., Schrappe-Bächer M., and Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem 34 (1988) 1787-1789
41. de Larrañaga G.F., Bocassi A.R., Puga L.M., Alonso B.S., and Benetucci J.A. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res 110 (2003) 93-98
42. Ross A.C., Armentrout R., O'Riordan M.A., Storer N., Rizk N., Harrill D., et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 49 (2008) 499-506
43. Zangerle R., Sarcletti M., Gallati H., Reibnegger G., Wachter H., and Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 7 (1994) 1149-1156
44. Rodríguez-Carranza S.I., and Aguilar-Salinas C.A. Metabolic abnormalities in patients with HIV infection. Rev Invest Clin 56 (2004) 193-208
45. Schroecksnadel K., Zangerle R., Bellmann-Weiler R., Garimorth K., Weiss G., and Fuchs D. Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection. Curr Drug Metab 8 (2007) 225-236